In this article, we will look at the 11 High Growth Healthcare Stocks to Buy Now.
On March 26, Stephanie Link, Hightower chief investment strategist, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends, where investors can find opportunities, and the effects of the Iran war. She was of the view that the situation right now is of maximum uncertainty, but if we wait for certainty, we are likely going to miss some great opportunities for some high-quality blue-chip companies that got hit with the downdraft with everything else. The timing of the war matters greatly, according to her, because if it is shorter-term, we can get through this, and the economy would continue to chug along, which would be a good thing. If it’s a longer term, we might slog around, but it is still important to take advantage of the dislocations.
READ ALSO: 15 Best Undervalued Stocks Under $50 to Invest In Now AND 12 Undervalued Defensive Stocks for 2026.
Link further said that if you sold last year during Liberation Day and that time period, you would have missed a 34% rally from the lows. If you sold during the 2023 Silicon Valley Bank collapse, you would have missed 78%. If you sold during COVID, you would have missed 198% recovery. She noted that all of these events happened in the March April time frame, which is the second-worst period seasonally in the year, behind September, which is the worst. She is thus trying to think about a year from now, and where we would be then. She hopes the war will be behind us by then, and also believes we will have higher stock prices.
With these broader market trends in view, let’s look at the best high growth healthcare stocks to buy now.
Our Methodology
We used stock screeners to make a list of healthcare stocks with a high 5-year revenue growth rate (over 25%). We then selected the top 11 most popular among elite hedge funds as of Q3 2025. We sourced the hedge fund data from Insider Monkey’s database. The stocks are ranked in ascending order of hedge fund sentiment.
Note: All data was recorded on March 26.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
11 High Growth Healthcare Stocks to Buy Now
11. Zai Lab Limited (NASDAQ:ZLAB)
Zai Lab Limited (NASDAQ:ZLAB) is one of the best high growth healthcare stocks to buy now. JPMorgan cut the price target on Zai Lab Limited (NASDAQ:ZLAB) to $32 from $39 on March 18, reiterating an Overweight rating on the shares. The rating update came after the firm updated models in the smid-cap biotechnology space.
In its fiscal Q4 and full-year 2025 financial results, Zai Lab Limited (NASDAQ:ZLAB) reported that total revenues grew 17% year-over-year to $127.6 million for fiscal Q4 2025, and 15% year-over-year to $460.2 million for the full-year 2025. The company further reported that Zocilurtatug pelitecan (zoci) is on track to attain the status of Zai Lab Limited’s (NASDAQ:ZLAB) first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026.
Management also stated that the company is advancing a differentiated global pipeline, including ZL-1503 (IL-13/IL-31Rα), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1/IL-12), and ZL-1311 (MUC17/CD3 TCE), with key regional programs also continuing to advance. This includes KarXT approval in China with commercial launch preparations underway, as well as pivotal data readouts for povetacicept in IgAN and elegrobart in TED expected in 2026.
Zai Lab Limited (NASDAQ:ZLAB) is a biopharmaceutical company that develops and commercializes therapies addressing medical conditions with unmet needs in autoimmune disorders, oncology, infectious diseases, and neuroscience. The company’s products include Zejula, Optune, Qinlock, and Nuzyra.
10. ImmunityBio Inc. (NASDAQ:IBRX)
ImmunityBio Inc. (NASDAQ:IBRX) is one of the best high growth healthcare stocks to buy now. On March 24, the FDA posted a warning letter to its site, stating that its Office of Prescription Drug Promotion “reviewed the promotional communications, a direct-to-consumer broadcast advertisement submitted by ImmunityBio Inc. (NASDAQ:IBRX), under cover of Form FDA 2253 and a DTC podcast titled, ‘Is the FDA BLOCKING Life Saving Cancer Treatments?’ regarding Anktiva…”. It added that complaints were received by the FDA Bad Ad Program regarding promotional communications for Anktiva, and the FDA determined that “the TV ad and podcast are false or misleading.
Reuters reported the same day that ImmunityBio Inc. (NASDAQ:IBRX) has been directed by the FDA to cease the TV ad and podcast or take it down, and also submit a written response within 15 working days addressing the concerns described in the letter. The company told Reuters in an email that the process of reviewing the agency’s letter has begun, and it aims to respond within the requested timeframe to address the matter.
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.
9. BioNTech SE (NASDAQ:BNTX)
BioNTech SE (NASDAQ:BNTX) is one of the best high growth healthcare stocks to buy now. On March 11, BMO Capital cut the price target on BioNTech SE (NASDAQ:BNTX) to $128 from $143 and reiterated an Outperform rating on the shares. The firm told investors in a research note that the company’s underwhelming 2026 COVID guide and confusing CEO departure messaging inject uncertainty ahead of BioNTech’s “major year for data”. It added that factors such as the uncertainty regarding the new leadership in light of a vast mid-to-late-stage pipeline and accelerating COVID revenue erosion give the firm pause on the stock.
BioNTech SE (NASDAQ:BNTX) also received a rating update from Morgan Stanley on March 11. The firm cut the price target on the stock to $125 from $134 and maintained an Overweight rating on the shares, telling investors that the company surprisingly announced a leadership transition in conjunction with its Q4 report. This overshadowed the fiscal Q4 results and the initial 2026 guidance. However, the firm added that it sees shares as undervalued ahead of a number of data read-outs following the selloff in the stock.
BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that creates messenger RNA (mRNA) therapeutics and vaccines to address serious diseases such as cancer and infectious diseases. It specializes in developing and manufacturing immunotherapies for patient-specific approaches.
8. Legend Biotech Corporation (NASDAQ:LEGN)
Legend Biotech Corporation (NASDAQ:LEGN) is one of the best high growth healthcare stocks to buy now. RBC Capital cut the price target on Legend Biotech Corporation (NASDAQ:LEGN) to $62 from $66 on March 11, reiterating an Outperform rating on the shares. The rating update came after the company released its fiscal Q4 results, telling investors in a research note that it sees a considerable disconnect between the share price and the fundamentals of the business. It added that the management’s execution on several aspects of the Carvykti opportunity has been strong, with factors such as improving real-world safety, impressive Overall Survival data, expanding manufacturing, and consistent double-digit revenue growth.
Legend Biotech Corporation (NASDAQ:LEGN) also received a rating update from Morgan Stanley on March 11. The firm cut the price target on the stock to $49 from $50, reiterating an Overweight rating on the shares and telling investors that it updated estimates after the company released its fiscal Q4 financial report. It, however, added that the firm is awaiting additional data from the CARTITUDE-5 study and the earlier-stage in vivo pipeline this year.
Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms. The company operates in the US, China, and other geographical segments.
7. Lantheus Holdings, Inc. (NASDAQ:LNTH)
Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the best high growth healthcare stocks to buy now. On March 17, Jefferies lifted the price target on Lantheus Holdings, Inc. (NASDAQ:LNTH) to $110 from $105, reaffirming a Buy rating on the shares. The firm stated that after comments at a recent conference and a meeting with the company, it is updating its prostate-specific membrane antigen positron emission tomography, or PSMA PET, model and Lantheus Holdings, Inc.’s (NASDAQ:LNTH) pricing assumptions. Jefferies further stated that it now models PSMA PET market volume growth of roughly 20% in 2025 and 10%-11% in 2026, and PYLARIFY TruVu commercial rollout in 4Q26, with meaningful contribution in 2027 and beyond.
The rating update came the same day Lantheus Holdings, Inc. (NASDAQ:LNTH) announced that the U.S. Food and Drug Administration extended its review of the New Drug Application for LNTH-2501 (Gallium 68 edotreotide) by three months to June 29, 2026, with the extension not related to the efficacy or safety data of LNTH-2501.
Lantheus Holdings, Inc. (NASDAQ:LNTH) provides diagnostic imaging and nuclear medicine products, developing products that support healthcare professionals in patient management and outcomes and help clinicians detect cardiovascular disease. The company’s operations are divided into the U.S. and International geographical segments.
6. Liquidia Corporation (NASDAQ:LQDA)
Liquidia Corporation (NASDAQ:LQDA) is one of the best high growth healthcare stocks to buy now. Wells Fargo raised the price target on Liquidia Corporation (NASDAQ:LQDA) to $51 from $44 on March 23, reiterating an Overweight rating on the shares and telling investors that it believes the pulmonary hypertension market is poised to change. It added that with key opinion leader feedback from a Respimat developer, and counter to current market sentiment, the firm sees the company’s L606 as competitive with Insmed’s TPIP.
Liquidia Corporation (NASDAQ:LQDA) also received a rating update from Oppenheimer on March 12. The firm lifted the price target on the stock to $19 from $16, reiterating an Underperform rating on the shares and giving credit to the company’s team for executing a strong early launch of YUTREPIA in pulmonary arterial hypertension/pulmonary hypertension associated with interstitial lung disease. It posted net product sales of $148.3 million in fiscal year 2025 despite what it continues to hear from physicians on YUTREPIA not being meaningfully differentiated. Oppenheimer believes that the immediate success speaks more to the growing need in PAH/PH-ILD, which the firm underestimated.
Liquidia Corporation (NASDAQ:LQDA) is a holding company involved in, through its subsidiary, developing and commercializing biopharmaceutical products and novel product development used in PRINT technology.
While we acknowledge the potential of LQDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LQDA and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 High Growth Healthcare Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
